Daniele Veritti

19PUBLICATIONS
60CO-AUTHORS
Optical technologyAutoimmunityOther chemical sciences not elsewhere classifiedChemical and thermal processes in energy and combustionNanomedicine
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (19)

|Jul 06, 2026
Switching to aflibercept 8 mg in neovascular age-related macular degeneration: real-world outcomes according to switch indication.

|Jun 25, 2026
Iridology: Biological plausibility, clinical evidence, and implications for ophthalmic practice : A position paper of the Associazione Pazienti Malattie Oculari (APMO).

|Jun 21, 2026
Comment to: Hashiya N, Maruko I, Maruko R et al. Increased intraocular pressure immediately after aflibercept 8 mg intravitreal injection for neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol (2026) 264:1611-1617. doi:10.1007/s00417-026-07117-3.

|Apr 02, 2026
Immediate Sequential Bilateral Cataract Surgery: Are We Overstating the Case? [Letter].

Pier Luigi Surico, Daniele Veritti, Valentina Sarao

|Feb 26, 2026
Reducing the Carbon Footprint of Neovascular Age-Related Macular Degeneration Therapy: Environmental Impact of Transitioning to Aflibercept 8 mg.

Daniele Veritti, Micaela Misciagna, Cristian Teatino

|Feb 25, 2026
AI-assisted analysis of early fluid dynamics following aflibercept 8 mg in treatment-naïve neovascular AMD.

Daniele Veritti, Valentina Sarao, Asia Amelia Martin

Pageof 4

Frequent Collaborators

17 joint publications

Paolo Lanzetta

12 joint publications

Valentina Sarao

2 joint publications

Marco Lombardo

2 joint publications

Enrico Borrelli